Genzyme

bluebird bio hires Susanna High and Andrew Obenshain

Monday, December 5, 2016

bluebird bio, a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, has announced two new appointments as part of the company’s ongoing preparation for commercial readiness. Susanna High was named chief operating officer and Andrew Obenshain was named senior vice president and head of Europe.

[Read More]

Halloran Consulting Group expands Regulatory and Development Team

Friday, November 4, 2016

Halloran Consulting Group, a national consultancy guiding life science companies to optimize development and performance, has announced the expansion of its regulatory and development team with the hiring of additional, highly specialized consultants, Iva Toudjarska, Ph.D., MBA, as principal consultant, Amanda Ceres, MS, as senior consultant and Keri Siggers, Ph.D., as consultant II. Earlier this year, Michelle Rose, Ph.D., was hired as principal consultant, to further enhance the company’s ability to deliver regulatory strategies and services.

[Read More]

Sanofi, Johns Hopkins partner on multiple sclerosis research

Monday, May 16, 2016

Sanofi Genzyme, the specialty care global business unit of Sanofi, has announced a research collaboration with the Johns Hopkins School of Medicine that will focus on novel strategies aimed at advancing the understanding of underlying causes of disease progression in multiple sclerosis (MS). The collaboration, under guidance by a joint committee of representatives from Sanofi Genzyme and the Johns Hopkins Multiple Sclerosis Center, will leverage certain technologies and methodologies designed to inform new therapeutic approaches to treating disease progression.

[Read More]

Epizyme appoints Matthew Ros chief operating officer

Friday, May 6, 2016

Epizyme, a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, has expanded its senior leadership team with the addition of Matthew Ros, who joins the company as chief operating officer. In this role, Ros will be responsible for directing and operationalizing Epizyme’s launch readiness efforts for tazemetostat, and will report to Epizyme’s president and chief executive officer, Robert Bazemore.

[Read More]

The long wave goodbye to phantom PIs

Friday, April 15, 2016

Efforts to reduce the number of phantom investigators—principal investigators (PIs) who are not adequately supervising their staff and clinical trials—appear to be having a measurable impact. But problems associated with, and the issues that cause, phantom PIs and their causes linger.

[Read More]